PRESS RELEASE published on 07/11/2024 at 07:30, 2 years 4 months ago Eleventh acquisition in 2024: Mutares has successfully completed the acquisition of Wilda Transport och Entreprenad AB and NU Entreprenad AB from Wilton Invest AB Mutares SE & Co. KGaA completes the acquisition of Wilda Transport och Entreprenad AB and NU Entreprenad AB from Wilton Invest AB, strengthening Terranor AB with EUR 10 million revenues in 2023 Acquisition Revenues Mutares SE & Co. KGaA Wilda Transport Och Entreprenad AB Terranor AB
PRESS RELEASE published on 07/11/2024 at 07:30, 2 years 4 months ago Gerresheimer Remains on Track in 1st Half Year 2024 Gerresheimer reports 1.7% revenue growth and 2.9% adjusted EBITDA increase in 1st half 2024, with Plastics & Devices division showing dynamic growth and improved margin Revenue Growth Gerresheimer Adjusted EBITDA Increase Plastics & Devices Division Guidance Confirmed
PRESS RELEASE published on 07/11/2024 at 07:30, 2 years 4 months ago DRONE VOLT annonce le lancement d'une augmentation de capital ouverte à tous avec maintien du droit préférentiel de souscription DRONE VOLT lance une augmentation de capital avec maintien du droit préférentiel de souscription, visant jusqu'à 2,6 millions d'euros, pour financer sa croissance. Opportunité d'investissement stratégique Croissance Investissement Augmentation De Capital Droit Préférentiel De Souscription DRONE VOLT
PRESS RELEASE published on 07/11/2024 at 07:30, 2 years 4 months ago Inside Information / Other news releases GenSight Biologics launches a newsletter for retail investors providing updates, news articles, conferences, and financial figures in French, available via subscription on the company's website Subscription Retail Investors Newsletter French GenSight Biologics
PRESS RELEASE published on 07/11/2024 at 07:30, 2 years 4 months ago Informations privilégiées / Autres communiqués GenSight Biologics lance une lettre d'information destinée aux investisseurs particuliers en France, présentant des actualités et des informations sur la société et ses projets innovants Investisseurs Particuliers GenSight Biologics Thérapies Géniques Maladies Neurodégénératives Lettre D'information
PRESS RELEASE published on 07/11/2024 at 07:29, 2 years 4 months ago Fielmann Group grows HY1/2024 sales +12% over 2023, improves profitability Fielmann Group reports 12% sales growth in HY1/2024, with improved profitability and outlook for Vision 2025. Digitalization and international expansion drive growth Profitability Digitalization Fielmann Group HY1/2024 Sales Vision 2025
PRESS RELEASE published on 07/11/2024 at 07:15, 2 years 4 months ago Inside Information / Other news releases Eurofins provides update to key stakeholders on actions responding to Muddy Waters' reports and plans for related party transactions. Additionally, the company addresses cash accounting and corporate governance Corporate Governance Muddy Waters Related Party Transactions Stakeholders Eurofins
PRESS RELEASE published on 07/11/2024 at 07:05, 2 years 4 months ago Heidelberg Pharma Reports on First Half-Year 2024 and the Course of Business Heidelberg Pharma AG reports positive preliminary efficacy data for HDP-101 in multiple myeloma clinical trial. Key events include AACR Meeting presentation & FDA Orphan Drug Designation Clinical Trial HDP-101 Heidelberg Pharma AG AACR Meeting FDA Orphan Drug Designation
REGULATED PRESS RELEASE published on 07/11/2024 at 07:01, 2 years 4 months ago Biophytis obtient l’autorisation IND de la FDA pour démarrer son étude OBA de phase 2 dans l’obésité Biophytis obtient l'autorisation IND de la FDA pour lancer l'étude OBA de phase 2 dans l'obésité avec BIO101 (20-hydroxyecdysone), visant à améliorer la force musculaire. Le professeur Marc-André Cornier dirigera l'étude multicentrique aux Etats-Unis Biophytis BIO101 Obésité Autorisation IND Étude OBA
REGULATED PRESS RELEASE published on 07/11/2024 at 07:01, 2 years 4 months ago Biophytis obtains IND approval from the FDA to start its phase 2 OBA study in obesity Biophytis obtains FDA approval to start phase 2 OBA study in obesity with BIO101 (20-hydroxyecdysone), focusing on muscle strength improvement. Study led by Prof. Marc-André Cornier to start mid-2024 in the USA Biophytis FDA Approval Obesity Treatment BIO101 Phase 2 OBA Study
Published on 11/11/2026 at 14:00, 33 minutes ago PPX Mining Reports Callanquitas Operating Results for the First Nine Months of 2026
Published on 11/11/2026 at 14:00, 33 minutes ago NuRAN Wireless Board Approves Growth Strategy to Scale Recurring Revenue from 5,000+ Contracted Towers
Published on 11/11/2026 at 13:15, 1 hour 18 minutes ago Amarc Extends 2026 Exploration Program at the Duke District: Initiates Drilling Program at Established Porphyry Copper-Gold Targets
Published on 11/11/2026 at 13:00, 1 hour 33 minutes ago NiobiumX Mining Reports Results of Ground Radiometric Survey at Shipshaw, Maps Two Distinct Radiometric Signatures Across the Core Claims, and Moves to a High-Resolution Airborne Survey of the Full 2,686-Hectare Package
Published on 11/11/2026 at 13:13, 1 hour 20 minutes ago Elmos Semiconductor SE and AGIBOT showcase Humanoid Robotics at electronica 2026
Published on 11/11/2026 at 13:05, 1 hour 28 minutes ago SwitchBot Introduces Curtain Track 4 for Smarter Curtains with Less Upkeep
Published on 11/11/2026 at 12:05, 2 hours 28 minutes ago H.I.G. Capital Signs Definitive Agreement to Acquire Majority Stake in go asia
Published on 11/11/2026 at 12:05, 2 hours 28 minutes ago EYKON brings digital revenue metering into the digital substation
Published on 11/11/2026 at 11:46, 2 hours 47 minutes ago ABO Energy GmbH & Co. KGaA intends to notify a Restructuring Project under the StaRUG
Published on 11/10/2026 at 18:00, 20 hours 33 minutes ago Déclaration du nombre total des droits de vote et du nombre d’actions au 31 octobre 2026
Published on 11/10/2026 at 17:45, 20 hours 48 minutes ago Damartex / Descriptif du programme de rachat d'actions
Published on 11/10/2026 at 17:35, 20 hours 58 minutes ago ENGIE - Déclaration du nombre total d'actions et de droits de vote au 31 octobre 2026
Published on 11/10/2026 at 17:31, 21 hours 1 minute ago CNP Assurances SA annonce le succès de l’émission d’une obligation subordonnée Tier 2 de 500 M€.